These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29019093)

  • 1. Triptans and CGRP blockade - impact on the cranial vasculature.
    Benemei S; Cortese F; Labastida-Ramírez A; Marchese F; Pellesi L; Romoli M; Vollesen AL; Lampl C; Ashina M;
    J Headache Pain; 2017 Oct; 18(1):103. PubMed ID: 29019093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
    Gupta S; Villalón CM
    Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Migraine and cluster headache - the common link.
    Vollesen AL; Benemei S; Cortese F; Labastida-Ramírez A; Marchese F; Pellesi L; Romoli M; Ashina M; Lampl C;
    J Headache Pain; 2018 Sep; 19(1):89. PubMed ID: 30242519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effects associated with current and prospective antimigraine pharmacotherapies.
    González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288.
    Knight YE; Edvinsson L; Goadsby PJ
    Neuropeptides; 1999 Feb; 33(1):41-6. PubMed ID: 10657470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine.
    Edvinsson L
    Headache; 2017 May; 57 Suppl 2():47-55. PubMed ID: 28485848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks].
    Stepień A; Jagustyn P; Trafny EA; Widerkiewicz K
    Neurol Neurochir Pol; 2003; 37(5):1013-23. PubMed ID: 15174248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Triptans and calcitonin gene-related peptide (CGRP) receptor antagonists].
    Negoro K
    Rinsho Shinkeigaku; 2012; 52(11):971-2. PubMed ID: 23196486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L; Haanes KA; Warfvinge K; Krause DN
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.
    Mathew PG; Klein BC
    Headache; 2019 Sep; 59(8):1421-1426. PubMed ID: 31318457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.
    Wattiez AS; Sowers LP; Russo AF
    Expert Opin Ther Targets; 2020 Feb; 24(2):91-100. PubMed ID: 32003253
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
    Jiang Y; Huang ZL
    Medicine (Baltimore); 2022 Jun; 101(24):e29361. PubMed ID: 35713436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
    Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
    Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rizatriptan on the expression of calcitonin gene-related peptide and cholecystokinin in the periaqueductal gray of a rat migraine model.
    Yao G; Han X; Hao T; Huang Q; Yu T
    Neurosci Lett; 2015 Feb; 587():29-34. PubMed ID: 25524408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin and CGRP in migraine.
    Aggarwal M; Puri V; Puri S
    Ann Neurosci; 2012 Apr; 19(2):88-94. PubMed ID: 25205974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.